Avalo Therapeutics Inc
(AVTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,842 | -6,151 | -3,238 | -16,050 | -13,532 |
| Depreciation Amortization | 17 | 11 | 6 | 20 | 21 |
| Accounts payable and accrued liabilities | 318 | -4 | -209 | N/A | -322 |
| Other Working Capital | -317 | 955 | 43 | -2,640 | 98 |
| Other Operating Activity | 208 | 388 | 329 | 3,160 | 2,184 |
| Operating Cash Flow | $-6,615 | $-4,800 | $-3,069 | $-15,510 | $-11,551 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -20 | N/A | N/A | -10 | -20 |
| Investing Cash Flow | $-20 | $N/A | $N/A | $-10 | $-20 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 9,640 |
| Debt Repayment | -1,024 | -253 | N/A | N/A | N/A |
| Other Financing Activity | -776 | -546 | -16 | 23,850 | 14,241 |
| Financing Cash Flow | $-1,799 | $-799 | $-16 | $23,850 | $23,880 |
| Beginning Cash Position | 11,742 | 11,742 | 11,742 | 3,420 | 3,422 |
| End Cash Position | 3,308 | 6,143 | 8,657 | 11,740 | 15,731 |
| Net Cash Flow | $-8,434 | $-5,600 | $-3,085 | $8,320 | $12,310 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,615 | -4,800 | -3,069 | -15,510 | -11,551 |
| Capital Expenditure | -20 | N/A | N/A | N/A | -20 |
| Free Cash Flow | -6,635 | -4,800 | -3,069 | -15,510 | -11,570 |